Table 3.

Effect Sizes (Outcomes) for Statistically Significant Predictors and Moderators (a)

Variable	Non Specific Predictor	Moderator favoring IPSRT + Quetiapine	Moderator favoring IPSRT + Placebo	Comment
Young Mania Rating Scale (YMRS)	0.11 (Change in Functional Assessment Short Test)		-0.08 (Treatment Response; ≥50% reduction in HRSD-25 scores from baseline to endpoint)	Higher YMRS score predicted more rapid improvement in functioning (F=6.037, p=0.016) and was associated with increased likelihood of response if assigned to IPSRT + placebo (OR=0.872, p=0.048)
Multidimensional Assessment of Thymic States (MATHYS)	-0.01 (Change in Hamilton Rating Scale for Depression; HRSD-25)	-0.04 (Change in Functional Assessment Short Test)		Hyperreactivity predicted faster improvement in depression (F=5.243, p=0.025) and more rapid improvement in functioning in those assigned to IPSRT + quetiapine (F=5.947, p=0.017)
Reverse Neurovegetative symptoms	0.11 (Change in HRSD-25)			Fewer atypical depression symptoms was associated with faster improvement in depression (F=7.087, p=0.009)
Panic-Agoraphobic Spectrum Self-Report (PAS-SR)	0.02 (Change in HRSD-25)			Lower PAS-SR scores were associated with more rapid improvement in depression (F=10.738, p=0.002)
Composite Scale of Morningness (CSM)	0.57 (Change in Body Mass Index; BMI)	-0.06 (Change in HRSD-25)		Eveningness showed a trend toward predicting greater BMI reductions (F=3.572, p=0.060) and morningness was associated with faster improvement in depression in those assigned to IPSRT + quetiapine (F=7.219, p=0.009)
Treatment Preference	0.49 (Treatment Response; ≥50% reduction in HRSD-25 scores from baseline to endpoint)			Receiving preferred treatment was associated with increased likelihood of response (OR=4.48, p=0.026)

(a) Effect sizes are expressed as standardized regression coefficients. Effect sizes for moderators are derived from the variable X treatment interaction term and those for predictors from the main effect of the variable.